Full Press Release Details
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in February:
Guggenheim Securities Emerging Outlook: Biotech SummitDate:February 11, 2026Time: 10:30 a.m. ETFormat:Fireside ChatLocation: New York, NY
Oppenheimer 36thAnnual Healthcare Life Sciences ConferenceDate:February 25, 2026Time: 8:40 a.m. ETFormat:Fireside ChatLocation: VirtualTo access a live webcast of these events, as well as an archived recording, please visit theInvestors & Mediasection of the Company’s website atwww.sab.bio.
About SAB BIOSAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine™, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. For more information, visitwww.sab.bio.